

# Non-Small Cell Lung Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/NEC23E4FD4FEN.html>

Date: June 2020

Pages: 4664

Price: US\$ 2,500.00 (Single User License)

ID: NEC23E4FD4FEN

## Abstracts

Non-Small Cell Lung Cancer - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features

dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 65, 327, 273, 23, 249, 46 and 12 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 16, 22, 51 and 4 molecules, respectively. Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Non-Small Cell Lung Cancer - Overview

Non-Small Cell Lung Cancer - Therapeutics Development

Non-Small Cell Lung Cancer - Therapeutics Assessment

Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development

Non-Small Cell Lung Cancer - Drug Profiles

Non-Small Cell Lung Cancer - Dormant Projects

Non-Small Cell Lung Cancer - Discontinued Products

Non-Small Cell Lung Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020  
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by 4D Pharma Plc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by A&G Pharmaceutical Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by ABM Therapeutics Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by AC Bioscience SA, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by ACEA Therapeutics Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Achilles Therapeutics Ltd, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by AcuityBio Corp, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics SA, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Advanced BioDesign, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Adze Biotechnology Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Agilvax Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Agios Pharmaceuticals Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by AIM ImmunoTech Inc, H1 2020  
Non-Small Cell Lung Cancer - Pipeline by Akeso Inc, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc  
4D Pharma Plc  
4SC AG  
A&G Pharmaceutical Inc  
A. Menarini Industrie Farmaceutiche Riunite Srl  
AbbVie Inc  
Ability Pharmaceuticals SL  
ABM Therapeutics Inc  
AC Bioscience SA  
ACEA Therapeutics Inc  
Achilles Therapeutics Ltd  
AcuityBio Corp  
Adaptimmune Therapeutics Plc  
ADC Therapeutics SA  
Aduro BioTech Inc  
Advanced BioDesign  
Advaxis Inc  
Advenchen Laboratories LLC  
Adze Biotechnology Inc  
Agenus Inc  
Agilvax Inc



Agios Pharmaceuticals Inc  
AIM ImmunoTech Inc  
Akeso Inc  
Alethia Biotherapeutics Inc  
Alkermes Plc  
Alligator Bioscience AB  
Allist Shanghai Pharmaceutical Technology Co Ltd  
Almac Discovery Ltd  
Alpha Biopharma  
Alphamab Oncology  
Altum Pharmaceuticals Inc  
ALX Oncology Inc  
amcure GmbH  
Amgen Inc  
AmMax Bio Inc  
Amphivena Therapeutics Inc  
Andarix Pharmaceuticals Inc  
Anew Oncology Inc  
AnHeart Therapeutics Inc  
Anhui Anke Biotechnology (Group) Co Ltd  
Antapodia Therapeutics Inc  
Antengene Corp  
AP Biosciences Inc  
Apexigen Inc  
Apollomics Inc  
Apotex Inc  
Aprea Therapeutics AB  
Aptarion biotech AG  
Araxes Pharma LLC  
Arch Oncology Inc  
Arcus Biosciences Inc  
Aro Biotherapeutics Co  
Arvinas Inc  
Asana BioSciences LLC  
Ascenta Therapeutics Inc  
Ascentage Pharma Group International  
Astellas Pharma Inc  
AstraZeneca Plc  
Atreca Inc

AUM Biosciences Pte Ltd  
Aurigene Discovery Technologies Ltd  
Aurobindo Pharma Ltd  
Axelar AB  
Basilea Pharmaceutica Ltd  
Batu Biologics Inc  
Bavarian Nordic A/S  
Bayer AG  
BeiGene Ltd  
Beijing Biostar Technologies Ltd  
Beijing Eastern Biotech Co Ltd  
Beijing Hanmi Pharmaceutical Co Ltd  
Beijing Kawin Technology Share-Holding Co Ltd  
Beijing Luzhu Biotechnology Co Ltd  
Beijing Mabworks Biotech Co Ltd  
Beijing Pearl Biotechnology LLC  
BerGenBio ASA  
Beta Pharma Inc  
Betta Pharmaceuticals Co Ltd  
BeyondSpring Inc  
Bicycle Therapeutics Plc  
Binjiang Pharma, Inc.  
Bio-Path Holdings Inc  
Bio-Thera Solutions Ltd  
BioAtla LLC  
Biocad  
BIOCND Inc  
Biocon Ltd  
Biohaven Pharmaceutical Holding Company Ltd  
BioIntegrator Ltd  
BioInvent International AB  
BioLineRx Ltd  
BioMarck Pharmaceuticals Ltd  
BioMed Valley Discoveries Inc  
BioNTech SE  
Biosion Inc  
Biothera Pharmaceutical Inc  
Bioven Group  
BioXpress Therapeutics SA

BJ Bioscience Inc  
Blueprint Medicines Corp  
Boehringer Ingelheim International GmbH  
Boston Biomedical Inc  
Boston Pharmaceuticals Inc  
BriaCell Therapeutics Corp  
Bridge Biotherapeutics Inc  
BrightPath Biotherapeutics Co Ltd  
Bristol-Myers Squibb Co  
Calithera Biosciences Inc  
CanBas Co Ltd  
Candel Therapeutics  
Cantargia AB  
CARsgen Therapeutics Ltd  
CAS-Lamvac Biotech Co Ltd  
Cascade Prodrug Inc  
CDR-Life Inc  
Cellatoz Therapeutics Inc  
Celldex Therapeutics Inc  
Cellestia Biotech AG  
Cellmid Ltd  
Celltrion Inc  
Cellular Biomedicine Group Inc  
Cellworks Group Inc  
Celon Pharma SA  
Centaurus Biopharma Co Ltd  
Centurion BioPharma Corp  
Centus Biotherapeutics Ltd  
Checkmate Pharmaceuticals Inc  
Checkpoint Therapeutics Inc  
Chi Cheung (Shanghai) Biomedical Co Ltd  
Chia Tai Tianqing Pharmaceutical Group Co Ltd  
Chineo Med Beijing Co Ltd  
Chiome Bioscience Inc  
Chipscreen Biosciences Ltd  
Chong Kun Dang Pharmaceutical Corp  
Chugai Pharmaceutical Co Ltd  
Cipla BioTec Pvt Ltd  
Cleveland BioLabs Inc

Cloaked Therapeutics LLC  
Clovis Oncology Inc  
Co-D Therapeutics Inc  
Compugen Ltd  
Constellation Pharmaceuticals Inc  
Convert Pharmaceuticals SA  
Corcept Therapeutics Inc  
Cortice Biosciences Inc  
Corvus Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
CSPC Pharmaceutical Group Ltd  
CStone Pharmaceuticals Co Ltd  
Cumberland Pharmaceuticals Inc  
Cureport Inc  
Cyclica Inc  
Cytocom Inc  
Cytocraft Bio-Tech Development Co Ltd  
CytomX Therapeutics Inc  
DAE HWA Pharmaceutical Co Ltd  
Daiichi Sankyo Co Ltd  
Debiopharm International SA  
Deciphera Pharmaceuticals Inc  
DEKK-TEC Inc  
DelMar Pharmaceuticals Inc  
Delta-Fly Pharma Inc  
DiNonA Inc  
Dizal (Jiangsu) Pharmaceutical Co Ltd  
Domainex Ltd  
Dr. Reddy's Laboratories Ltd  
Dragonfly Therapeutics Inc  
Druggability Technologies Holdings Ltd  
Dynavax Technologies Corp  
eFFECTOR Therapeutics Inc  
EirGenix Inc  
Eisai Co Ltd  
Eleison Pharmaceuticals LLC  
Eli Lilly and Co  
Elicio Therapeutics  
EnGeneIC Ltd

Enochian Biosciences Inc  
EntreChem SL  
Enzene Biosciences Ltd  
EpicentRx Inc  
Epidestiny Inc  
EpimAb Biotherapeutics Inc  
Epizyme Inc  
Epygen Biotech Pvt Ltd  
Ergon Pharmaceuticals LLC  
Esanex Inc  
Essential Biotechnology LLC  
Eudendron Srl  
Eutilex Co Ltd  
Evaxion Biotech ApS  
Evelo Biosciences Inc  
Evestra Inc  
Evotec SE  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
FibroStatin SL  
Five Prime Therapeutics Inc  
Fochon Pharma Inc  
Fochon Pharmaceutical Ltd  
Forbius  
Formosa Pharmaceuticals Inc  
Fresenius SE & Co KGaA  
Fujifilm Holdings Corp  
G&E Corp  
G1 Therapeutics Inc  
Galectin Therapeutics Inc  
Galera Therapeutics Inc  
GC Pharma  
GEEN Biotechnology Inc  
GEMoaB Monoclonals GmbH  
Gene Techno Science Co Ltd  
GeneFrontier Corp  
Genelux Corp  
Genentech Inc

Geneos Therapeutics Inc  
Genexine Inc  
GenFleet Therapeutics (Shanghai) Inc  
Genmab AS  
Genocea Biosciences Inc  
Genome & Co  
Genor BioPharma Co Ltd  
Genosco Inc  
Genprex Inc

## I would like to order

Product name: Non-Small Cell Lung Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/NEC23E4FD4FEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NEC23E4FD4FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970